Yesterday, May 5, 2016, 52 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.82 to $4,152,000.00.

Highlighted Stocks Traded by Insiders:

Provident Financial Holdings (PROV) - FREE Research Report

Gale Richard L, who is Senior Vice President at Provident Financial Holdings, sold 5,000 shares at $18.00 on May 5, 2016. Following this transaction, the Senior Vice President owned 78,838 shares meaning that the stake was reduced by 5.96% with the 5,000-share transaction.

The shares most recently traded at $18.13, up $0.13, or 0.72% since the insider transaction. Historical insider transactions for Provident Financial Holdings go as follows:

  • 4-Week # shares bought: 1,200
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 1,200
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 1,200
  • 24-Week # shares sold: 5,000

The average volume for Provident Financial Holdings has been 23,100 shares per day over the past 30 days. Provident Financial Holdings has a market cap of $148.3 million and is part of the financial sector and banking industry. Shares are down 4.55% year-to-date as of the close of trading on Thursday.

Provident Financial Holdings, Inc. operates as the holding company for Provident Savings Bank, F.S.B. that provides community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The stock currently has a dividend yield of 2.71%. The company has a P/E ratio of 20.8. Currently, there are no analysts who rate Provident Financial Holdings a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PROV - FREE

TheStreet Quant Ratings

rates Provident Financial Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Provident Financial Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ADMA Biologics (ADMA) - FREE Research Report

Lenz Brian, who is Chief Financial Officer at ADMA Biologics, bought 2,500 shares at $6.50 on May 5, 2016. Following this transaction, the Chief Financial Officer owned 8,500 shares meaning that the stake was boosted by 41.67% with the 2,500-share transaction.

Mond James, who is Cso/Cmo at ADMA Biologics, bought 770 shares at $6.50 on May 5, 2016. Following this transaction, the Cso/Cmo owned 3,389 shares meaning that the stake was boosted by 29.4% with the 770-share transaction.

The shares most recently traded at $12.00, up $5.50, or 45.83% since the insider transaction. Historical insider transactions for ADMA Biologics go as follows:

TheStreet Recommends

  • 4-Week # shares bought: 4,000
  • 12-Week # shares bought: 4,000
  • 24-Week # shares bought: 13,111

The average volume for ADMA Biologics has been 7,200 shares per day over the past 30 days. ADMA Biologics has a market cap of $116.1 million and is part of the health care sector and drugs industry. Shares are up 60.26% year-to-date as of the close of trading on Friday.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases.

Exclusive Offer: Get the latest Stock Analysis on ADMA - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Validus Holdings (VR) - FREE Research Report

Kudera Andrew E., who is EVP, Chief Actuary at Validus Holdings, sold 10,000 shares at $46.72 on May 5, 2016. Following this transaction, the EVP, Chief Actuary owned 39,093 shares meaning that the stake was reduced by 20.37% with the 10,000-share transaction.

The shares most recently traded at $47.07, up $0.35, or 0.74% since the insider transaction. Historical insider transactions for Validus Holdings go as follows:

  • 4-Week # shares sold: 1,015
  • 12-Week # shares bought: 48
  • 12-Week # shares sold: 12,839
  • 24-Week # shares bought: 48
  • 24-Week # shares sold: 123,894

The average volume for Validus Holdings has been 447,700 shares per day over the past 30 days. Validus Holdings has a market cap of $3.8 billion and is part of the financial sector and insurance industry. Shares are up 1.53% year-to-date as of the close of trading on Thursday.

Validus Holdings, Ltd. provides reinsurance coverage, insurance coverage, and insurance linked securities management services worldwide. It operates through four segments: Validus Re, Talbot, Western World, and AlphaCat. The stock currently has a dividend yield of 2.99%. The company has a P/E ratio of 10.5. Currently, there is 1 analyst who rates Validus Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VR - FREE

TheStreet Quant Ratings

rates Validus Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Validus Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.